Related Experiment Videos
Levamisole, the story and the lessons.
1Janssen Research Foundation, Beerse, Belgium.
International Journal of Immunopharmacology
|April 1, 1992
Summary
Levamisole, initially an anthelmintic, has evolved into an important immunotropic agent. Recent trials highlight its effectiveness as an adjuvant treatment for operable colon cancer, underscoring its enduring role in cancer therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Levamisole's historical trajectory spans from anthelmintic use to immunomodulation.
- Its clinical significance resurged with adjuvant therapy for colon cancer.
Purpose of the Study:
- To review the historical use and evolving applications of levamisole.
- To synthesize evidence from experimental models and clinical trials in cancer treatment.
Main Methods:
- Literature review of levamisole's history and applications.
- Analysis of experimental tumor models and clinical data.
- Evaluation of large-scale controlled trials in resectable colon cancer.
Main Results:
- Levamisole demonstrated efficacy as an adjuvant treatment for operable colon cancer.
- Evidence from diverse cancer types and experimental models supports its immunotropic properties.
Conclusions:
- Levamisole remains a significant therapeutic agent, particularly in adjuvant colon cancer treatment.
- The study emphasizes the role of serendipity in drug discovery and development.